We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock
PLXP

Delisted

PLXP was delisted on the 12th of April, 2023.

Back to rankings

16 hedge funds and large institutions have $11.7M invested in PLx Pharma Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $6.51M → $11.7M (+$5.19M)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$272K
2
6CM
683 Capital Management
New York
+$133K
3
CS
Credit Suisse
Switzerland
+$121K
4
Northern Trust
Northern Trust
Illinois
+$44.4K
5
Wells Fargo
Wells Fargo
California
+$902

Top Sellers

Rank Fund Capital Flow
1
Brown Advisory
Brown Advisory
Maryland
-$112K
2
Millennium Management
Millennium Management
New York
-$107K
3
TRCT
Tower Research Capital (TRC)
New York
-$13.6K
4
UBS Group
UBS Group
Switzerland
-$6.51K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWAM
1
Park West Asset Management
California
$8.13M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.63M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$768K +$272K +61,400 +79%
UOTTAIMCU
4
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$346K – – –
HWA
5
Heritage Way Advisors
Illinois
$230K – – –
6CM
6
683 Capital Management
New York
$166K +$133K +30,000 New
CS
7
Credit Suisse
Switzerland
$151K +$121K +27,394 New
Millennium Management
8
Millennium Management
New York
$85K -$107K -24,224 -61%
Fayez Sarofim & Co
9
Fayez Sarofim & Co
Texas
$76K – – –
Northern Trust
10
Northern Trust
Illinois
$55K +$44.4K +10,043 New
CWM
11
Cranbrook Wealth Management
Michigan
$41K – – –
UBS Group
12
UBS Group
Switzerland
$13K -$6.51K -1,473 -39%
BlackRock
13
BlackRock
New York
$11K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$2K -$13.6K -3,084 -88%
Wells Fargo
15
Wells Fargo
California
$2K +$902 +204 +80%
Morgan Stanley
16
Morgan Stanley
New York
$1K – – –
Brown Advisory
17
Brown Advisory
Maryland
– -$112K -34,536 Closed

PLXP Hedge Fund Activity: Q4 2020 in Review

16 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q4 2020, worth a combined $11.7M — up 80% from $6.51M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PLXP positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $272K. The largest seller was Brown Advisory, exiting entirely with an estimated $112K sold.

  • 16 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q4 2020, up from 15 in Q3 2020.
  • Funds reported $11.7M of PLx Pharma Inc. Common Stock stock for Q4 2020, up 80% quarter-over-quarter.
  • 3 funds opened new PLx Pharma Inc. Common Stock positions in Q4 2020 and 2 closed out, a net change of +1 holder.
  • The largest PLx Pharma Inc. Common Stock buyer in Q4 2020 was Renaissance Technologies, an estimated $272K added.
  • The largest PLx Pharma Inc. Common Stock seller in Q4 2020 was Brown Advisory, an estimated $112K sold.

Based on aggregated 13F filings for Q4 2020.